Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of nivolumab alone or nivolumab + ipilimumab versus investigator's choice chemotherapy in MSI-H/dMMR metastatic colorectal cancer
2018-000040-26Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in colorectal cancer (CRC), metastatic colorectal adenocarcinoma (mCRC) and microsatellite unstable colorectal cancer (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-Free Survival. Started May 2019; status: active.
02
Drugs
nivolumabipilimumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)microsatellite unstable colorectal cancer
Beyond the preview
Go deeper on 2018-000040-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000040-26.